2014
DOI: 10.1016/j.cclet.2014.01.019
|View full text |Cite
|
Sign up to set email alerts
|

Design of novel bis-benzimidazole derivatives as DNA minor groove binding agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 11 publications
(3 citation statements)
references
References 14 publications
0
3
0
Order By: Relevance
“…ODAA was synthesized by acetylation of 4,4 ′ -oxydianiline using acetic anhydride [16]. Details of the synthesis reaction of ODAA were given in Section S.5.…”
Section: Synthesis and Standardization Of Odaamentioning
confidence: 99%
See 1 more Smart Citation
“…ODAA was synthesized by acetylation of 4,4 ′ -oxydianiline using acetic anhydride [16]. Details of the synthesis reaction of ODAA were given in Section S.5.…”
Section: Synthesis and Standardization Of Odaamentioning
confidence: 99%
“…Then, we decided to synthesize this compound in order to use as a reference standard in our study. Preparation of ODAA was performed by the acetylation of 4,4 ′oxydianiline using acetic anhydride as described [16]. Thin-layer chromatography (TLC) results showed that the synthesis reaction of ODAA completed successfully.…”
Section: Identification Of Odaa In Acetaminophen Batches and Its Subs...mentioning
confidence: 99%
“…The benzimidazole groove‐binders 1a (Hoechst 33342) and 1b (Hoechst 33258) can selectively bind to small grooves rich in base pairs to produce cytotoxic effects by inhibiting DNA topoisomerase I and DNA helicase, so Hoechst 33342 and Hoechst 33258 as lead compounds have been widely reported (Issar et al, 2015; Singh et al, 1992). Hoechst 33258 showed anti‐L1210 mouse leukemia activity and positive effect in various solid tumors which led to the compound entering phase I clinical trials in humans, such as pancreatic cancer (Mmler et al, 1971; Wang et al, 2014). A subsequent Phase II trial of pancreatic cancer showed that Hoechst 33258 had a therapeutic effect on patients with advanced pancreatic cancer (Kraut et al, 1991; Wang et al, 2018).…”
Section: Introductionmentioning
confidence: 99%